COST-EFFECTIVENESS OF FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY AND CHRONIC HEART FAILURE IN AUSTRIA

被引：4
|
作者：
Walter, E. [1 ]
Bauer, M. [1 ]
Ressl, S. [1 ]
机构：
[1] Inst Pharmaecon Res, Vienna, Austria
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.876
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV107
引用
收藏
页码：A392 / A392
页数：1
相关论文
共 50 条
  • [41] A PATIENT-LEVEL COST-EFFECTIVENESS ANALYSIS OF IRON ISOMALTOSIDE VERSUS FERRIC CARBOXYMALTOSE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN THE UNITED KINGDOM
    Pollock, R.
    Muduma, G.
    VALUE IN HEALTH, 2020, 23 : S373 - S373
  • [42] Safety and Efficacy of Ferric Carboxymaltose in Heart Failure With Preserved Ejection Fraction and Iron Deficiency
    Shabeer, Hassan
    Samore, Naseer
    Ahsan, Salman
    Gondal, Muhammad Umer Riaz
    Shah, Badar U. Din
    Ashraf, Amna
    Faraz, Maria
    Malik, Jahanzeb
    CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (01)
  • [43] Cost-effectiveness of candesartan in Germany for patients with chronic heart failure
    Voelkl, M
    Pirk, O
    Juenger, V
    VALUE IN HEALTH, 2005, 8 (06) : A96 - A96
  • [44] ECONOMIC EVALUATION OF FERRIC CARBOXYMALTOSE IN PATIENTS WITH CHRONIC HEART FAILURE AND IRON DEFICIENCY: AN ANALYSIS FOR GREECE BASED ON FAIR-HF TRIAL
    Mylonas, C.
    Kourlaba, G.
    Berberian, K.
    Maniadakis, N.
    VALUE IN HEALTH, 2014, 17 (07) : A486 - A486
  • [45] Economic evaluation of ferric carboxymaltose in patients with chronic heart failure and iron deficiency: an analysis for Greece based on FAIR-HF trial
    Milonas, C.
    Parissis, J.
    Kourlaba, G.
    Karavidas, A.
    Farmakis, D.
    Filippatos, G.
    Maniadakis, N.
    EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 : 355 - 355
  • [46] Testing for iron deficiency and use of ferric carboxymaltose in patients with heart failure: need for implementation? data from the swedish heart failure registry
    Becher, P. M. Peter Moritz
    Schrage, B.
    Benson, L.
    Dahlstrom, U.
    Lund, L.
    Savarese, G.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 182 - 182
  • [47] Iron deficiency and safety of ferric carboxymaltose in patients with acute heart failure. AHF-ID study
    Jacob, Javierq
    Miro, Oscar
    Ferre, Carles
    Borraz-Ordas, Carmen
    Llopis-Garcia, Guillermo
    Comabella, Rosa
    Fernandez-Canadas, Jose Maria
    Mercado, Amparo
    Roset, Alex
    Richard-Espiga, Fernando
    Valero-Domenech, Amparo
    Martinez-Gimeno, Jose Luis
    Martin-Sanchez, Francisco Javier
    Llorens, Pere
    Berrocal-Gil, Pablo
    Perez-Dura, Maria Jose
    alvarez-Perez, Jose Maria
    Lopez-Diez, Pilar
    Herrero-Puente, Pablo
    Comin-Colet, Josep
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2020, 74 (10)
  • [48] Efficacy of Intravenous Ferric Carboxymaltose in Heart Failure Patients with Iron Deficiency Anemia: A Meta-analysis of 6271 Patients
    Taha, Amira Mohamed
    Elsaeidy, Ahmed Saad
    Nada, Sarah A.
    Sharma, Sadish
    Ghonaim, Mohamed M.
    Ahsan, Areeba
    Mourid, Marina Ramzy
    Abouelmagd, Khaled
    CLINICAL DRUG INVESTIGATION, 2024, 44 (12) : 879 - 896
  • [49] Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency
    Ponikowski, Piotr
    van Veldhuisen, Dirk J.
    Comin-Colet, Josep
    Ertl, Georg
    Komajda, Michel
    Mareev, Viacheslav
    McDonagh, Theresa
    Parkhomenko, Alexander
    Tavazzi, Luigi
    Levesque, Victoria
    Mori, Claudio
    Roubert, Bernard
    Filippatos, Gerasimos
    Ruschitzka, Frank
    Anker, Stefan D.
    EUROPEAN HEART JOURNAL, 2015, 36 (11) : 657 - 668
  • [50] Effectiveness and safety of ferric carboxymaltose to treat iron deficiency anemia in cancer patients.
    Aktas, Burak Yasin
    Kayku, Vildan Eda
    Aslan, Alma
    Kertmen, Neyran
    Dizdar, Omer
    Yalcin, Suayib
    Aksoy, Sercan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345